OTCMKTS:TLPPF Telix Pharmaceuticals (TLPPF) Stock Price, News & Analysis → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free TLPPF Stock Alerts $11.55 -0.04 (-0.35%) (As of 06/10/2024 ET) Add Compare Share Share Today's Range$11.45▼$11.8850-Day Range$8.14▼$12.4752-Week Range$5.30▼$12.61Volume6,021 shsAverage Volume6,746 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Telix Pharmaceuticals alerts: Email Address Ad Traders AgencyHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About Telix Pharmaceuticals Stock (OTCMKTS:TLPPF)Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.Read More TLPPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLPPF Stock News HeadlinesJune 1, 2024 | americanbankingnews.comTelix Pharmaceuticals (OTCMKTS:TLPPF) Trading Up 12%May 19, 2024 | investing.comTelix Pharmaceuticals plans Nasdaq listingMay 17, 2024 | finance.yahoo.comTelix Files Registration Statement for Proposed Initial Public Offering in the United StatesMay 17, 2024 | globenewswire.comTelix Files Registration Statement for Proposed Initial Public Offering in the United StatesApril 29, 2024 | seekingalpha.comCLRPF Clarity Pharmaceuticals LtdApril 18, 2024 | markets.businessinsider.comUBS Keeps Their Buy Rating on Telix Pharmaceuticals Ltd. (TLPPF)April 16, 2024 | finance.yahoo.comTelix Pharmaceuticals Limited (TLPPF)April 11, 2024 | finance.yahoo.comTelix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.April 11, 2024 | businesswire.comTelix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.March 21, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Telix Pharmaceuticals Ltd. (TLPPF)March 18, 2024 | finance.yahoo.comQDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical TherapyMarch 11, 2024 | finance.yahoo.comAppointment of Dr Darren Patti to Group Chief Operating OfficerMarch 5, 2024 | markets.businessinsider.comAustralian Stocks: Telix (TLX) Bolsters Supply Chain with AU$126M ARTMS DealFebruary 23, 2024 | markets.businessinsider.comStrong Buy Rating for Telix Pharmaceuticals Amidst Revenue Surge and Market Expansion OpportunitiesFebruary 22, 2024 | msn.comTelix Pharmaceuticals GAAP EPS of A$1.61, revenue of A$502.55MFebruary 7, 2024 | msn.comQSAM to be acquired by Telix for $33.1M plus $90M CVRJanuary 2, 2024 | morningstar.comTelix Pharmaceuticals Ltd Ordinary SharesDecember 26, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Telix Pharmaceuticals Ltd. (TLPPF)December 25, 2023 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Telix Pharmaceuticals Ltd. (TLPPF)December 11, 2023 | finance.yahoo.comFirst Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging AgentDecember 6, 2023 | finance.yahoo.comPositive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCSNovember 8, 2023 | finance.yahoo.comTelix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic RegionOctober 19, 2023 | msn.comTelix Pharmaceuticals reports Q3 resultsOctober 18, 2023 | finance.yahoo.comProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and TolerabilitySeptember 6, 2023 | finance.yahoo.comTelix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANMSee More Headlines Receive TLPPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:TLPPF CUSIPN/A CIKN/A Webtelixpharma.com Phone61-3-3093-3897FaxN/AEmployees234Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Darren Smith B.Bus. (Age 59)FCPA, M.B.A., Group Chief Financial Officer Comp: $380.97kDr. Andreas Kluge M.D. (Age 59)Ph.D., Chief Medical Advisor & Non-Executive Director Comp: $28.68kMr. Richard Valeix M.B.A. (Age 49)Group Chief Commercial Officer Comp: $425.87kMr. Darren Patti (Age 52)Group Chief Operating Officer Dr. Michael Wheatcroft B.Sc.BSc(Hons), Ph.D., Ph.D., (Cantab), Chief ScientistMr. Craig UlrickChief Information OfficerMs. Kyahn Williamson B.A.Senior Vice President of Corporate Communications & Investor RelationsMs. Melanie Farris (AGIAACG, ACIS) BComn, B.Com., GradDip, M.A.I.C., Senior VP of Global Governance, Risk & ComplianceMs. Lena Moran-Adams L.L.B.Group General CounselThomas FrommVice President of SalesMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors TLPPF Stock Analysis - Frequently Asked Questions Should I buy or sell Telix Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Telix Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" TLPPF shares. View TLPPF analyst ratings or view top-rated stocks. How have TLPPF shares performed in 2024? Telix Pharmaceuticals' stock was trading at $6.8750 at the start of the year. Since then, TLPPF stock has increased by 68.0% and is now trading at $11.55. View the best growth stocks for 2024 here. How do I buy shares of Telix Pharmaceuticals? Shares of TLPPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:TLPPF) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
